|
|
Vaccine Detail
|
NYVAC-Pf7 |
| Vaccine Information |
- Vaccine Name: NYVAC-Pf7
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Vaccine Ontology ID: VO_0004794
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Human
- Antigen: PfCS, PfSSP2, LSA1, MSP1, SERA, AMA1, and Pfs25 (Ockenhouse et al., 1998)
- CS from P. falciparum
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- LSA-1 from Plasmodium falciparum
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MSP-1 from P. falciparum
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- AMA1 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Pfs25 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- SSP2 from Plasmodium falciparum
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- SERA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: (Ockenhouse et al., 1998)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
|
| References |
Ockenhouse et al., 1998: Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. The Journal of infectious diseases. 1998; 177(6); 1664-1673. [PubMed: 9607847].
|
|
